- Home
- RIGL vs RNAC Comparison
RIGL vs RNAC Comparison
Compare RIGL & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- RNAC
- Stock Information
- Founded
- RIGL 1996
- RNAC 2007
- Country
- RIGL United States
- RNAC United States
- Employees
- RIGL N/A
- RNAC N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- RNAC Biotechnology: Pharmaceutical Preparations
- Sector
- RIGL Health Care
- RNAC Health Care
- Exchange
- RIGL Nasdaq
- RNAC Nasdaq
- Market Cap
- RIGL 335.5M
- RNAC 316.1M
- IPO Year
- RIGL 2000
- RNAC 2016
- Fundamental
- Price
- RIGL $41.50
- RNAC $11.23
- Analyst Decision
- RIGL Buy
- RNAC Strong Buy
- Analyst Count
- RIGL 5
- RNAC 4
- Target Price
- RIGL $38.20
- RNAC $40.00
- AVG Volume (30 Days)
- RIGL 845.0K
- RNAC 55.2K
- Earning Date
- RIGL 08-05-2025
- RNAC 08-07-2025
- Dividend Yield
- RIGL N/A
- RNAC N/A
- EPS Growth
- RIGL N/A
- RNAC N/A
- EPS
- RIGL 5.43
- RNAC N/A
- Revenue
- RIGL $267,921,000.00
- RNAC $1,026,000.00
- Revenue This Year
- RIGL $14.41
- RNAC N/A
- Revenue Next Year
- RIGL $15.97
- RNAC N/A
- P/E Ratio
- RIGL $7.64
- RNAC N/A
- Revenue Growth
- RIGL 105.62
- RNAC N/A
- 52 Week Low
- RIGL $12.00
- RNAC $8.46
- 52 Week High
- RIGL $43.72
- RNAC $26.50
- Technical
- Relative Strength Index (RSI)
- RIGL 86.20
- RNAC 45.84
- Support Level
- RIGL $38.43
- RNAC $10.50
- Resistance Level
- RIGL $41.25
- RNAC $11.80
- Average True Range (ATR)
- RIGL 2.50
- RNAC 0.74
- MACD
- RIGL 0.89
- RNAC -0.07
- Stochastic Oscillator
- RIGL 89.85
- RNAC 45.08
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.